Nalaganje...
Breast Cancer Immunotherapy: Facts and Hopes
Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of PD-1/PD-L1 antagonists in small numbers of metastatic breast cancer patients. Clinical activity appears more likely if the tumor is triple negative, PD-L1+, and/or harbors...
Shranjeno v:
| izdano v: | Clin Cancer Res |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5796849/ https://ncbi.nlm.nih.gov/pubmed/28801472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-3001 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|